US 12,187,744 B2
IRAK4 degraders and synthesis thereof
William Leong, Watertown, MA (US); and Dharyl Charles Wilson, Heftfordshire (GB)
Assigned to Kymera Therapeutics, Inc., Watertown, MA (US)
Filed by Kymera Therapeutics, Inc., Watertown, MA (US)
Filed on Oct. 28, 2022, as Appl. No. 18/050,883.
Claims priority of provisional application 63/263,274, filed on Oct. 29, 2021.
Prior Publication US 2023/0257399 A1, Aug. 17, 2023
Int. Cl. C07D 519/00 (2006.01); C07D 487/04 (2006.01)
CPC C07D 519/00 (2013.01) [C07D 487/04 (2013.01); C07B 2200/07 (2013.01)] 18 Claims
 
1. A composition comprising compound I-1:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, and three or more impurity compounds selected from the group consisting of:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.